Q2 FY26 Earnings January 29, 2026 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial ...

Summary of ResMed's Conference Call Company Overview - **Company**: ResMed - **Market Cap**: Approximately $37 billion [2] - **Revenue**: $5.3 billion in the trailing 12 months with gross margins around 59-62% and net operating profit margins above 30% [3][30] - **Business Segments**: - Sleep health and breathing health solutions - Software business contributing 12% of revenue [3][4] - **Geographic Distribution**: 58% of revenue from the US, Canada, and Latin America; strong presence in Europe and Asia [3] Investment Opportunity - **Target Markets**: Large addressable markets including sleep apnea, insomnia, and chronic obstructive pulmonary disease [4][5] - **Megatrends**: - Integration of sleep apnea detection in wearables by Big Tech (e.g., Apple, Samsung) [5][44] - Increased patient flow into healthcare due to new GLP-1 drugs [6][22] - **Innovation and Operating Excellence**: Strong cash flow generation of $1.8 billion in the last 12 months, with a focus on R&D, share buybacks, and acquisitions [6][30] Product Innovations - **New Products**: - AirTouch N30i and AirTouch F30i masks with fabric technology for improved comfort [12][53] - AI-enabled medical devices to enhance patient adherence to therapy [13][15] - **Digital Health Initiatives**: Launch of a digital sleep health concierge named Dawn to assist patients in managing their sleep health [16] Market Dynamics - **Competitive Landscape**: - ResMed maintains a strong lead over competitors in the US and globally, with a focus on innovation and patient adherence [35][36] - A major competitor has returned to the market, but ResMed has continued to grow its market share [37] - **Regulatory Environment**: - CPAP therapy excluded from the latest round of competitive bidding, which is seen as a positive for the industry [38][39] Patient Engagement and Education - **Primary Care Physician Education**: - 60,000 CME courses on sleep apnea have been downloaded, with 77% of physicians indicating they will change their practice protocols [26] - **Patient Adherence**: - Patients on GLP-1 medications show higher adherence rates to CPAP therapy, with a 10.8% higher probability of starting CPAP treatment [23][50] Financial Performance - **Capital Distribution**: Over $3.7 billion distributed in the last three years, with a focus on R&D and shareholder returns [30][31] - **Share Repurchases**: Plans for at least $600 million in share repurchases in fiscal year 2026 [31] Future Outlook - **Growth Projections**: Anticipated high single-digit growth with continued leverage on the P&L [33] - **Manufacturing Expansion**: New facilities in the US to support increased manufacturing capacity, aligning with the "Made in America" initiative [29] Conclusion - ResMed is positioned as a compelling investment opportunity due to its strong market presence, innovative product offerings, and strategic focus on patient engagement and education [34]

Financial Performance & Growth - ResMed's Last Twelve Months (LTM) Q1 2026 revenue reached $5.3 billion[10] - The company's LTM Q1 2026 GAAP operating margin was 33%, and the non-GAAP operating margin was 35%[10] - Free cash flow for LTM Q1 FY26 was approximately $1.8 billion, representing a 31% year-over-year growth[16] - ResMed has a strong balance sheet with a net cash position of $715 million as of Q1 FY26[16] - Revenue grew at a Compound Annual Growth Rate (CAGR) of 12% (GAAP) and 14% (Non-GAAP) from LTM Q1 2021 to LTM Q1 2026[80] - EPS grew at a CAGR of 16% (GAAP) and 14% (Non-GAAP) from LTM Q1 2021 to LTM Q1 2026[80] Market & Strategy - ResMed targets a large and underpenetrated market, including over 1 billion people with sleep apnea and 480 million with COPD[17] - Less than 20% of the Obstructive Sleep Apnea (OSA) market is diagnosed or treated in the U.S., and less than 10% in the rest of the world[18] - ResMed invests 6% - 7% of revenue in Research and Development (R&D)[75] - The company anticipates high single-digit percentage revenue growth with earnings growth exceeding revenue growth, underpinned by its 2030 strategy[83]

Core Insights - Resmed Inc. (RMD) is experiencing strong demand for its mask portfolio, including AirFit and AirTouch, while also focusing on strategic acquisitions to enhance its Residential Care Software business [1][8] - The company is expanding into international markets, which shows promising growth potential [1][9] Financial Performance - Over the past year, RMD stock has increased by 2.1%, outperforming the industry decline of 1.5% and the S&P 500 rise of 14.7% [2] - Resmed has a market capitalization of $36.25 billion and an earnings yield of 4.4%, compared to the industry's flat yield [2] - The company has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 3.04% [2] Revenue Growth - In the first quarter of fiscal 2026, revenues from masks and other businesses grew by 12% year over year in the U.S., Canada, and Latin America, driven by resupply and new patient setups [3] - The acquisition of VirtuOx contributed additional revenues [3] - The Residential Care Software business saw a revenue increase of 6% on a reported basis and 5% in constant currency in the same quarter, supported by strong performances from MEDIFOX DAN and MatrixCare [6] Product Innovation - Resmed is focused on expanding its mask portfolio through new product innovations, recently launching two new variants under the AirTouch F30i mask platform [4] - The new products aim to enhance the comfort and options available in the fabric-based mask offerings [4] Strategic Acquisitions - The company has made strategic acquisitions, such as MEDIFOX DAN and MatrixCare, to bolster its Residential Care Software revenues [5] - Resmed is integrating its Residential Care Software business into its broader organization as part of its 2030 operating model [6] International Expansion - Resmed is targeting high-growth international markets, including China, South Korea, India, Brazil, and Eastern Europe, to improve patient quality of life and reduce healthcare costs [9] - Combined sales in the U.S., Canada, Latin America, Europe, and Asia increased by 10% in the first quarter of fiscal 2026 [9] Challenges - The company faces macroeconomic challenges, including geopolitical instability and supply chain constraints, which could impact demand and operating costs [10] - The competitive landscape for sleep-disordered breathing (SDB) products is intense, with significant competition from companies like Philips BV and DeVilbiss Healthcare [11] Earnings Estimates - The Zacks Consensus Estimate for RMD's fiscal 2026 earnings per share has increased by 0.2% to $10.81, with revenue estimates at $5.57 billion, reflecting an 8.3% increase from the previous year [12]

Financial Data and Key Metrics Changes - The company reported a trailing 12-month top-line growth of 12% and a non-GAAP EPS growth of 14%, indicating strong financial performance and operational leverage [26][27]. Business Line Data and Key Metrics Changes - The company launched several new products, including a generative AI product called Dawn and a Compliance Predictor, enhancing its digital health offerings [22][23]. - The company has increased its gross margin by 200-300 basis points year on year, reflecting improved profitability [25]. Market Data and Key Metrics Changes - The company aims to help over 500 million people by 2030 through its healthcare technologies, indicating a strong market focus and growth potential [24]. Company Strategy and Development Direction - The company has restated its 2030 strategy, focusing on product-led, customer-centric, and brand-enhanced growth, with an emphasis on increasing product velocity and profitable growth [25]. - The company is investing 6-7% of its revenues back into technology and 19% into sales and marketing to drive demand generation [27]. Management's Comments on Operating Environment and Future Outlook - Management highlighted the role of artificial intelligence as a tailwind for the company, with ongoing experiments and product launches aimed at improving patient outcomes [21]. - The company has successfully completed acquisitions, including Ectosense and VirtuOx, to enhance its service offerings in sleep apnea testing [28][29]. Other Important Information - The company has increased its share repurchase program from $100 million to $150 million per quarter, with discussions on further increases [28]. Q&A Session Summary Question: How is artificial intelligence a tailwind for the company? - Management discussed the launch of AI-driven products like Dawn and Compliance Predictor, which enhance patient engagement and improve therapy adherence [21][22][23].

Financial Data and Key Metrics Changes - The company reported a trailing 12-month top-line growth of 12% and a non-GAAP EPS growth of 14%, indicating strong financial performance and operational leverage [26][27]. Business Line Data and Key Metrics Changes - The company launched several new products, including a generative AI product called Dawn and a Compliance Predictor, enhancing its digital health offerings [22][23]. - The company has increased its gross margin by 200-300 basis points year on year, reflecting improved profitability [25]. Market Data and Key Metrics Changes - The company aims to improve the lives of 500 million people by 2030, indicating a strong commitment to expanding its market impact [24]. Company Strategy and Development Direction - The company has restated its 2030 strategy, focusing on product-led, customer-centric, and brand-enhanced growth models [25]. - The company is investing 6-7% of its revenues back into technology development and 19% into sales and marketing to drive demand [27]. Management's Comments on Operating Environment and Future Outlook - Management emphasized the role of artificial intelligence as a tailwind for the company, with ongoing experiments and product launches aimed at improving patient outcomes [22]. - The company has a goal of achieving high single-digit revenue growth annually through 2030, alongside double-digit growth in earnings per share [24]. Other Important Information - The company has engaged in strategic M&A activities, including the acquisition of Ectosense and VirtuOx, to enhance its service offerings in sleep apnea testing [28][29]. Q&A Session Summary Question: How is artificial intelligence a tailwind for the company? - Management highlighted the launch of AI-driven products like Dawn and Compliance Predictor, which enhance patient engagement and improve therapy adherence [22][23].